Outcomes of Intermediate Risk Non–muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled Trials

European Urology Oncology · Published 2026-07-01 · DOI 10.1016/j.euo.2026.04.017

Authors (14)

Wei Shen Tan, Ashish M. Kamat, Rebecca Lewis, Nuria Porta, Charlotte Ackerman, Thenmalar Vadiveloo, Steven Penegar, Alberto Martini, Luke Vale, Hugh Mostafid, Graeme MacLennan, Emma Hall, Rakesh Heer, John D. Kelly

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Tan, W., Kamat, A., Lewis, R., et al. (2026). Outcomes of Intermediate Risk Non–muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled Trials. European Urology Oncology. https://doi.org/10.1016/j.euo.2026.04.017

Related articles

• Oncological Outcomes of Different Managements of the Distal Ureter in Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma · European Urology Oncology · 2026 · Same journal
• Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non–muscle-invasive Bladder Cancer: A Multicenter Analysis of 1032 Patients · European Urology Oncology · 2026 · Same journal
• When Patients Refuse Radical Cystectomy: Integrating Trimodality Therapy in the Perioperative ICI/ADC Era · European Urology Oncology · 2026 · Same journal
• Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study · European Urology Oncology · 2026 · Same journal
• Individual Patient Data Validation of the EAU Definitions of BCG Failure in Patients with Non–muscle-invasive Urothelial Carcinoma of the Bladder: An International Multicenter Retrospective Study · European Urology Oncology · 2026 · Same journal
• Salvage High-intensity Focused Ultrasound for Prostate Cancer Recurrence after Radiotherapy (HIFI-2 Study) · European Urology Oncology · 2026 · Same journal
• PI-RADS v2 and Adverse Prostate Cancer Outcomes: A Cross-cohort Replication Study Across Three Centers · European Urology Oncology · 2026 · Same journal
• Study Protocol of OLIGOPELVIS 2–GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer · European Urology Oncology · 2026 · Same journal
• Adjusted Comparison of First-line Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-based Chemotherapy ± Avelumab Maintenance for the Treatment of Locally Advanced/Metastatic Urothelial Carcinoma · European Urology Oncology · 2026 · Same journal
• PROTEUS: A Practice-changing Trial, but Are We Ready to Embrace Perioperative Apalutamide for All High-risk Patients? · European Urology Oncology · 2026 · Same journal